主动脉瓣置换术后永久起搏器植入的发生率与危险因素
该单中心研究分析了2006至2017年5807例择期外科主动脉瓣置换(SAVR)和1292例经导管主动脉瓣置换(TAVR)患者,排除既往起搏器者。SAVR后新起搏器植入率为2.6%,TAVR后为9.7%(P<.0001)。TAVR后危险因素包括术前传导障碍和瓣膜类型,SAVR后无可靠危险因素。
要点
- TAVR后永久起搏器植入率9.7%,显著高于SAVR的2.6%。
- TAVR后起搏器植入与术前传导障碍及瓣膜类型相关。
- SAVR后未发现可靠的起搏器植入危险因素。
核心结论
- 当前时代高容量中心需建立主动脉瓣置换术后起搏器植入的基准。
- 术前传导障碍和经导管瓣膜类型影响TAVR后起搏器植入率。
- 这些数据为低危患者考虑TAVR时提供了参考基准。
研究设计与样本
- 单中心回顾性研究,纳入2006至2017年择期SAVR(伴或不伴冠脉搭桥)5807例和TAVR(伴或不伴冠脉介入)1292例。
- 排除既往永久起搏器患者,采用多变量逻辑回归分析起搏器植入危险因素。
主要发现
- SAVR后新永久起搏器植入151例(2.6%),TAVR后125例(9.7%),组间P<.0001。
- TAVR后起搏器植入危险因素包括术前传导障碍和瓣膜类型:SAPIEN 9.5%、SAPIEN XT 4.8%、SAPIEN 3 10%、CoreValve 30%、其他TAVR 10%。
- SAVR后无可靠起搏器植入危险因素;二叶瓣、机械瓣 vs 生物瓣、较高STS风险评分及同期冠脉搭桥均与风险升高无关。
临床怎么用
- TAVR术前应评估传导障碍和瓣膜类型以预判起搏器风险。
- 低危患者选择TAVR时需参考起搏器植入基准数据。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 仅纳入2006至2017年数据,瓣膜类型分布可能随时代变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Damage to the cardiac conduction system requiring permanent pacemaker implantation is a complication of aortic valve replacement (AVR) that may importantly affect quality of life. We investigated the prevalence of and preprocedure risk factors for new permanent pacemakers after surgical (SAVR) and transcatheter AVR (TAVR) at a single institution. METHODS: Preoperative variables and baseline electrocardiograms were reviewed for 5807 patients undergoing elective SAVR, with or without coronary artery bypass grafting, and 1292 undergoing TAVR, with or without percutaneous coronary intervention, from 2006 to 2017 at Cleveland Clinic. Patients with previous permanent pacemakers were excluded. Risk factors for permanent pacemaker implantation were identified using multivariable logistic regression analysis. RESULTS: New permanent pacemakers were implanted in 151 (2.6%) after SAVR and in 125 (9.7%) after TAVR (whole group SAVR vs TAVR, P <.0001). Risk factors for pacemaker implantation after TAVR included preoperative conduction disturbances and type of prosthesis (SAPIEN, 9.5%; SAPIEN XT, 4.8%; SAPIEN 3, 10% [Edwards Lifesciences, Irvine, CA]; CoreValve, 30% [Medtronic, Minneapolis, MN]; and other TAVR, 10%). There were no reliable risk factors for pacemaker implantation after SAVR. Bicuspid valves, mechanical vs bioprosthetic valves, higher Society of Thoracic Surgeons risk score, and concomitant coronary artery bypass grafting were not associated with elevated risk. CONCLUSIONS: At a high-volume institution in the current era, establishing a baseline for pacemaker implantation after AVR is necessary. Preoperative conduction disturbances and transcatheter valve type affect its prevalence. These data provide a benchmark that should be taken into account when considering TAVR in low-risk patients.
引用
- Levack MM, Kapadia SR, Soltesz EG, et al. Prevalence of and Risk Factors for Permanent Pacemaker Implantation After Aortic Valve Replacement. Ann Thorac Surg. 2019. PMID: 31034827. doi:10.1016/j.athoracsur.2019.03.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。